Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.

3 Apr 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Researchers test protease inhibitors with potential for prevention, treatment of norovirus infection

A Kansas State University-led team is researching ways to stop the spread of norovirus, a contagious stomach illness that infects one in 15 Americans each year, according to the Centers for Disease Control and Prevention.

25 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Einstein researchers to develop drug-impregnated intravaginal ring for HIV prevention in women

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.

11 Mar 2013

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.

11 Mar 2013

Two novel radiolabeled small molecules can help detect prostate cancer

Two novel radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to research published this month in The Journal of Nuclear Medicine.

6 Mar 2013

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

Sanford-Burnham Medical Research Institute and 60- Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics.

5 Mar 2013

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.

2 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

Pharmacokinetics News and Research

Further Reading

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Researchers test protease inhibitors with potential for prevention, treatment of norovirus infection

arGEN-X advances ARGX-112 into formal preclinical development

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

Einstein researchers to develop drug-impregnated intravaginal ring for HIV prevention in women

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Two novel radiolabeled small molecules can help detect prostate cancer

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Positive results from Neurim’s Piromelatine phase II study on insomnia

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News